| Primary immunodeficiency |
1.82 |
1.42e-1 |
33/38 (86.84%) |
IL2RG;IGLL1;CD79A;...
|
| B cell receptor signaling pathway |
1.77 |
1.62e-1 |
71/81 (87.65%) |
KRAS;CD79A;PPP3CB;...
|
| Pancreatic cancer |
1.72 |
1.90e-1 |
75/76 (98.68%) |
RALGDS;KRAS;ERBB2;...
|
| C-type lectin receptor signaling pathway |
1.69 |
2.01e-1 |
93/104 (89.42%) |
IKBKE;KRAS;RELB;...
|
| PD-L1 expression and PD-1 checkpoint pathway in cancer |
1.67 |
1.81e-1 |
79/89 (88.76%) |
KRAS;MAPK13;JAK1;...
|
| T cell receptor signaling pathway |
1.65 |
1.83e-1 |
93/104 (89.42%) |
KRAS;DLG1;MAPK13;...
|
| Measles |
1.54 |
2.19e-1 |
133/139 (95.68%) |
IL2RG;IKBKE;JAK1;...
|
| Insulin signaling pathway |
1.54 |
2.05e-1 |
121/137 (88.32%) |
PRKAR2B;PRKCZ;KRAS;...
|
| Rheumatoid arthritis |
1.54 |
1.93e-1 |
78/93 (83.87%) |
HLA-DQA1;ACP5;LTB;...
|
| Th1 and Th2 cell differentiation |
1.54 |
1.91e-1 |
80/92 (86.96%) |
IL2RG;HLA-DQA1;MAPK13;...
|
| Insulin resistance |
1.53 |
1.89e-1 |
96/108 (88.89%) |
PRKCZ;CD36;NOS3;...
|
| Fluid shear stress and atherosclerosis |
1.53 |
1.83e-1 |
123/139 (88.49%) |
PRKCZ;GSTA1;NOS3;...
|
| Oxidative phosphorylation |
1.52 |
1.92e-1 |
93/133 (69.92%) |
COX7A1;NDUFV1;ATP6V1C1;...
|
| TNF signaling pathway |
1.51 |
1.87e-1 |
103/112 (91.96%) |
MAP3K5;CASP7;CREB3L2;...
|
| Autoimmune thyroid disease |
1.50 |
1.99e-1 |
46/53 (86.79%) |
HLA-DQA1;GZMB;TG;...
|
| Endometrial cancer |
1.50 |
1.93e-1 |
56/58 (96.55%) |
KRAS;ERBB2;GADD45B;...
|
| ErbB signaling pathway |
1.49 |
1.94e-1 |
79/85 (92.94%) |
KRAS;ERBB2;SHC1;...
|
| Osteoclast differentiation |
1.49 |
1.87e-1 |
117/127 (92.13%) |
ACP5;FOSB;SIRPA;...
|
| Endocytosis |
1.49 |
1.81e-1 |
198/252 (78.57%) |
IL2RG;RAB11FIP1;CHMP6;...
|
| Thermogenesis |
1.49 |
1.75e-1 |
173/232 (74.57%) |
FGFR1;KRAS;MAP3K5;...
|
| Toll-like receptor signaling pathway |
1.49 |
1.69e-1 |
94/104 (90.38%) |
IKBKE;MAPK13;TRAF3;...
|
| VEGF signaling pathway |
1.49 |
1.65e-1 |
50/59 (84.75%) |
NOS3;KRAS;MAPKAPK2;...
|
| Th17 cell differentiation |
1.49 |
1.61e-1 |
95/107 (88.79%) |
IL2RG;HLA-DQA1;RUNX1;...
|
| Colorectal cancer |
1.47 |
1.84e-1 |
84/86 (97.67%) |
RALGDS;KRAS;RHOA;...
|
| JAK-STAT signaling pathway |
1.46 |
1.83e-1 |
146/162 (90.12%) |
IL2RG;JAK1;SOCS3;...
|
| Human T-cell leukemia virus 1 infection |
1.44 |
2.05e-1 |
197/219 (89.95%) |
IL2RG;HLA-DQA1;KRAS;...
|
| Choline metabolism in cancer |
1.44 |
2.03e-1 |
84/98 (85.71%) |
LYPLA1;PIP5K1B;RALGDS;...
|
| Non-alcoholic fatty liver disease |
1.44 |
2.02e-1 |
126/155 (81.29%) |
MAP3K5;CASP7;MAPK13;...
|
| Estrogen signaling pathway |
1.43 |
2.06e-1 |
119/137 (86.86%) |
GPER1;NOS3;KRAS;...
|
| Central carbon metabolism in cancer |
1.42 |
2.13e-1 |
67/70 (95.71%) |
FGFR1;KRAS;ERBB2;...
|
| Long-term depression |
-1.14 |
5.72e-1 |
55/60 (91.67%) |
PLCB1;GUCY1A2;GUCY1A1;...
|
| Peroxisome |
-1.14 |
5.84e-1 |
72/82 (87.8%) |
HMGCL;DECR2;MVK;...
|
| Complement and coagulation cascades |
-1.15 |
5.79e-1 |
76/85 (89.41%) |
C4BPA;C2;C1R;...
|
| Insulin secretion |
-1.15 |
5.84e-1 |
75/86 (87.21%) |
PLCB1;CAMK2G;KCNMB1;...
|
| Fanconi anemia pathway |
-1.15 |
5.88e-1 |
36/54 (66.67%) |
MLH1;PALB2;TELO2;...
|
| RNA transport |
-1.16 |
5.78e-1 |
128/186 (68.82%) |
EIF5B;KPNB1;PABPC4;...
|
| Glyoxylate and dicarboxylate metabolism |
-1.18 |
5.73e-1 |
23/30 (76.67%) |
GLUL;HAO1;SHMT1;...
|
| Glycine, serine and threonine metabolism |
-1.18 |
5.70e-1 |
31/40 (77.5%) |
AOC3;PIPOX;PSAT1;...
|
| Inflammatory mediator regulation of TRP channels |
-1.18 |
5.86e-1 |
82/98 (83.67%) |
MAPK14;PLCB1;PLCG1;...
|
| Transcriptional misregulation in cancer |
-1.22 |
5.82e-1 |
158/192 (82.29%) |
TSPAN7;CCNA2;TRAF1;...
|
| Taurine and hypotaurine metabolism |
-1.28 |
4.72e-1 |
8/11 (72.73%) |
CSAD;ADO
|
| Ascorbate and aldarate metabolism |
-1.29 |
4.90e-1 |
15/30 (50%) |
UGT2B17;ALDH1B1;ALDH9A1;...
|
| Glutamatergic synapse |
-1.29 |
5.04e-1 |
97/114 (85.09%) |
PLCB1;GLS2;HOMER2;...
|
| Drug metabolism |
-1.30 |
4.82e-1 |
78/151 (51.66%) |
ADH6;CYP2B6;CYP1A2;...
|
| Systemic lupus erythematosus |
-1.32 |
4.61e-1 |
45/135 (33.33%) |
C1S;C9;GRIN2B;...
|
| Vascular smooth muscle contraction |
-1.34 |
4.41e-1 |
113/133 (84.96%) |
PLCB1;GUCY1A2;GUCY1A1;...
|
| Glycosylphosphatidylinositol (GPI)-anchor biosynthesis |
-1.34 |
4.55e-1 |
20/26 (76.92%) |
PIGV;PIGL;PIGP;...
|
| Caffeine metabolism |
-1.34 |
4.80e-1 |
5/6 (83.33%) |
CYP2A6;CYP1A2;NAT2;...
|
| p53 signaling pathway |
-1.35 |
4.70e-1 |
63/73 (86.3%) |
STEAP3;CDKN2A;CCND1;...
|
| Proteasome |
-1.38 |
4.29e-1 |
44/46 (95.65%) |
PSMC2;PSMA6;PSMD7;...
|
| Bile secretion |
-1.38 |
4.65e-1 |
68/90 (75.56%) |
SLC22A1;UGT2B17;GNAS;...
|
| Purine metabolism |
-1.40 |
4.34e-1 |
102/129 (79.07%) |
ADA;NME4;GMPR2;...
|
| Neomycin, kanamycin and gentamicin biosynthesis |
-1.42 |
4.07e-1 |
5/5 (100%) |
HK1
|
| Ribosome |
-1.42 |
4.56e-1 |
113/158 (71.52%) |
RPSA;RPL19;MRPL13;...
|
| Sulfur relay system |
-1.43 |
4.78e-1 |
5/8 (62.5%) |
NFS1;MPST;MOCS2
|
| Protein export |
-1.46 |
4.66e-1 |
17/23 (73.91%) |
SEC11A;SEC61A2;HSPA5;...
|
| Dilated cardiomyopathy |
-1.47 |
5.15e-1 |
86/96 (89.58%) |
GNAS;TPM1;ADCY3;...
|
| Pyruvate metabolism |
-1.53 |
3.86e-1 |
41/47 (87.23%) |
ME2;ALDH1B1;PDHB;...
|
| Other glycan degradation |
-1.60 |
2.70e-1 |
13/18 (72.22%) |
MANBA;NEU1;HEXA;...
|
| Tyrosine metabolism |
-1.61 |
3.74e-1 |
30/36 (83.33%) |
MIF;FAH;ALDH3B1;...
|
